Adherex Technologies (FENC) Projected to Post Earnings on Tuesday

Key Points

• Adherex Technologies is set to announce its Q2 2025 earnings results on August 12th, with expectations of a loss of ($0.06) per share and revenue of $9.52 million.
• The company's stock recently traded down 4.1% to $7.98, with a market capitalization of $221.29 million.
• Analysts have upgraded Adherex Technologies to a "buy" rating, with a price target of $13.00, following positive earnings reports and insider stock movements.

Adherex Technologies (NASDAQ:FENC - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Adherex Technologies to post earnings of ($0.06) per share and revenue of $9.52 million for the quarter.

Adherex Technologies (NASDAQ:FENC - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.08. The firm had revenue of $8.51 million for the quarter, compared to analysts' expectations of $8.18 million. During the same quarter in the previous year, the firm posted $0.41 EPS. On average, analysts expect Adherex Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Adherex Technologies Stock Up 0.4%

Shares of NASDAQ:FENC traded up $0.03 during trading on Thursday, reaching $8.19. 13,726 shares of the company's stock traded hands, compared to its average volume of 77,617. The company has a 50-day simple moving average of $8.34 and a 200-day simple moving average of $7.02. Adherex Technologies has a fifty-two week low of $3.96 and a fifty-two week high of $9.30. The firm has a market cap of $227.80 million, a PE ratio of -16.06 and a beta of 0.40.

Insider Buying and Selling at Adherex Technologies

In related news, Director Rosty Raykov sold 10,000 shares of the stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $8.09, for a total transaction of $80,900.00. Following the completion of the sale, the director directly owned 55,878 shares of the company's stock, valued at $452,053.02. This trade represents a 15.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jeffrey S. Hackman bought 13,965 shares of the firm's stock in a transaction on Monday, May 19th. The shares were bought at an average price of $6.99 per share, for a total transaction of $97,615.35. Following the completion of the transaction, the chief executive officer directly owned 15,000 shares in the company, valued at approximately $104,850. This represents a 1,349.28% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 31,119 shares of company stock valued at $254,546. Company insiders own 11.76% of the company's stock.

Institutional Trading of Adherex Technologies

A hedge fund recently bought a new stake in Adherex Technologies stock. Jane Street Group LLC acquired a new stake in shares of Adherex Technologies Inc. (NASDAQ:FENC - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 14,718 shares of the company's stock, valued at approximately $90,000. Jane Street Group LLC owned about 0.05% of Adherex Technologies at the end of the most recent reporting period. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have commented on FENC. Wall Street Zen upgraded shares of Adherex Technologies from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. Craig Hallum raised their price objective on shares of Adherex Technologies from $12.00 to $13.00 and gave the company a "buy" rating in a report on Wednesday, May 14th. Finally, HC Wainwright reiterated a "buy" rating and set a $13.00 target price on shares of Adherex Technologies in a research note on Tuesday, May 20th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $13.00.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.